Intralymphatic immunotherapy

World Allergy Organization Journal

Thomas M Kündig²  Gabriela Senti¹ 

[1] Clinical Trials Center, University Hospital Zurich, Raemistrasse 100/MOU2, Zurich, CH-8091, Switzerland;Department of Dermatology, University Hospital Zurich, Zurich, Switzerland

关键词: Vaccination;    Intralympathic;    Allergen immunotherapy;    Administration routes;   

Others  :  1137472
DOI  :  10.1186/s40413-014-0047-7

 received in 2014-04-17, accepted in 2014-11-14,  发布年份 2015

【 摘 要 】

Gold Standard allergen-specific immunotherapy is associated with low efficacy because it requires either many subcutaneous injections of allergen or even more numerous sublingual allergen administrations to achieve amelioration of symptoms. Intralymphatic vaccination can maximize immunogenicity and hence efficacy. We and others have demonstrated that as few as three low dose intralymphatic allergen administrations are sufficient to effectively alleviate symptoms. Results of recent prospective and controlled trials suggest that this strategy may be an effective form of allergen immunotherapy.

【 授权许可】

   
2015 Senti and Kündig; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Frey JR, Wenk P: Experimental studies on the pathogenesis of contact eczema in the guinea-pig. Int Arch Allergy Appl Immunol 1957, 11:81-100.
• [2]Greter M, Hofmann J, Becher B: Neo-lymphoid aggregates in the adult liver can initiate potent cell-mediated immunity. PLoS Biol 2009, 7:e1000109.
• [3]Karrer U, Althage A, Odermatt B, Roberts CW, Korsmeyer SJ, Miyawaki S, Hengartner H, Zinkernagel RM: On the key role of secondary lymphoid organs in antiviral immune responses studied in alymphoplastic (aly/aly) and spleenless (Hox11(−)/-) mutant mice. J Exp Med 1997, 185:2157-2170.
• [4]Kundig TM, Bachmann MF, DiPaolo C, Simard JJ, Battegay M, Lother H, Gessner A, Kuhlcke K, Ohashi PS, Hengartner H, et al.: Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 1995, 268:1343-1347.
• [5]Zinkernagel RM, Ehl S, Aichele P, Oehen S, Kundig T, Hengartner H: Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol Rev 1997, 156:199-209.
• [6]Zinkernagel RM: Localization dose and time of antigens determine immune reactivity. Semin Immunol 2000, 12:163-171. discussion 257–344
• [7]Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF: Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 2008, 38:1404-1413.
• [8]Juillard GJ, Boyer PJ: Intralymphatic immunization: current status. Eur J Cancer 1977, 13:439-440.
• [9]Sigel MB, Sinha YN, VanderLaan WP: Production of antibodies by inoculation into lymph nodes. Methods Enzymol 1983, 93:3-12.
• [10]Nilsson BO, Svalander PC, Larsson A: Immunization of mice and rabbits by intrasplenic deposition of nanogram quantities of protein attached to Sepharose beads or nitrocellulose paper strips. J Immunol Methods 1987, 99:67-75.
• [11]Waeckerle-Men Y, Bruffaerts N, Liang Y, Jurion F, Sander P, Kundig TM, Huygen K, Johansen P: Lymph node targeting of BCG vaccines amplifies CD4 and CD8 T-cell responses and protection against Mycobacterium tuberculosis. Vaccine 2013, 31:1057-1064.
• [12]Lesimple T, Neidhard EM, Vignard V, Lefeuvre C, Adamski H, Labarriere N, Carsin A, Monnier D, Collet B, Clapisson G, et al.: Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients. Clin Cancer Res 2006, 12:7380-7388.
• [13]Mackensen A, Krause T, Blum U, Uhrmeister P, Mertelsmann R, Lindemann A: Homing of intravenously and intralymphatically injected human dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells. Cancer Immunol Immunother 1999, 48:118-122.
• [14]Grover A, Kim GJ, Lizee G, Tschoi M, Wang G, Wunderlich JR, Rosenberg SA, Hwang ST, Hwu P: Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes. Clin Cancer Res 2006, 12:5801-5808.
• [15]Brown K, Gao W, Alber S, Trichel A, Murphey-Corb M, Watkins SC, Gambotto A, Barratt-Boyes SM: Adenovirus-transduced dendritic cells injected into skin or lymph node prime potent simian immunodeficiency virus-specific T cell immunity in monkeys. J Immunol 2003, 171:6875-6882.
• [16]de Vries IJ, Lesterhuis WJ, Barentsz JO, Verdijk P, van Krieken JH, Boerman OC, Oyen WJ, Bonenkamp JJ, Boezeman JB, Adema GJ, et al.: Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 2005, 23:1407-1413.
• [17]De Vries IJ, Krooshoop DJ, Scharenborg NM, Lesterhuis WJ, Diepstra JH, Van Muijen GN, Strijk SP, Ruers TJ, Boerman OC, Oyen WJ, et al.: Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 2003, 63:12-17.
• [18]Lesimple T, Moisan A, Carsin A, Ollivier I, Mousseau M, Meunier B, Leberre C, Collet B, Quillien V, Drenou B, et al.: Injection by various routes of melanoma antigen-associated macrophages: biodistribution and clinical effects. Cancer Immunol Immunother 2003, 52:438-444.
• [19]Koopman G, Bogers WM, van Gils M, Koornstra W, Barnett S, Morein B, Lehner T, Heeney JL: Comparison of intranasal with targeted lymph node immunization using PR8-Flu ISCOM adjuvanted HIV antigens in macaques. J Med Virol 2007, 79:474-482.
• [20]Johansen P, Haffner AC, Koch F, Zepter K, Erdmann I, Maloy K, Simard JJ, Storni T, Senti G, Bot A, et al.: Direct intralymphatic injection of peptide vaccines enhances immunogenicity. Eur J Immunol 2005, 35:568-574.
• [21]Smith KA, Tam VL, Wong RM, Pagarigan RR, Meisenburg BL, Joea DK, Liu X, Sanders C, Diamond D, Kundig TM, et al.: Enhancing DNA vaccination by sequential injection of lymph nodes with plasmid vectors and peptides. Vaccine 2009, 27:2603-2615.
• [22]Maloy KJ, Erdmann I, Basch V, Sierro S, Kramps TA, Zinkernagel RM, Oehen S, Kundig TM: Intralymphatic immunization enhances DNA vaccination. Proc Natl Acad Sci U S A 2001, 98:3299-3303.
• [23]Heinzerling L, Basch V, Maloy K, Johansen P, Senti G, Wuthrich B, Storni T, Kundig TM: Critical role for DNA vaccination frequency in induction of antigen-specific cytotoxic responses. Vaccine 2006, 24:1389-1394.
• [24]Weber J, Boswell W, Smith J, Hersh E, Snively J, Diaz M, Miles S, Liu X, Obrocea M, Qiu Z, Bot A: Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma. J Immunother 2008, 31:215-223.
• [25]Tagawa ST, Lee P, Snively J, Boswell W, Ounpraseuth S, Lee S, Hickingbottom B, Smith J, Johnson D, Weber JS: Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma. Cancer 2003, 98:144-154.
• [26]Weber JS, Vogelzang NJ, Ernstoff MS, Goodman OB, Cranmer LD, Marshall JL, et al. A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors. J Immunother. 2011;34:556–67.
• [27]Ribas A, Weber JS, Chmielowski B, Comin-Anduix B, Lu D, Douek M, et al. Intra-lymph node prime-boost vaccination against Melan A and tyrosinase for the treatment of metastatic melanoma: results of a phase 1 clinical trial. Clin Cancer Res. 2011;17:2987–96.
• [28]Lehner T, Wang Y, Cranage M, Bergmeier LA, Mitchell E, Tao L, Hall G, Dennis M, Cook N, Brookes R, et al.: Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat Med 1996, 2:767-775.
• [29]Kawabata S, Miller CJ, Lehner T, Fujihashi K, Kubota M, McGhee JR, Imaoka K, Hioi T, Kiyono H: Induction of Th2 cytokine expression for p27-specific IgA B-cell responses after targeted lymph node immunization with simian immunodeficiency virus in rhesus macaques. J Infect Dis 1998, 177:26-33.
• [30]Lehner T, Mitchell E, Bergmeier L, Singh M, Spallek R, Cranage M, Hall G, Dennis M, Villinger F, Wang Y: The role of gammadelta T cells in generating antiviral factors and beta-chemokines in protection against mucosal simian immunodeficiency virus infection. Eur J Immunol 2000, 30:2245-2256.
• [31]Bogers WM, Bergmeier LA, Ma J, Oostermeijer H, Wang Y, Kelly CG, Ten Haaft P, Singh M, Heeney JL, Lehner T: A novel HIV-CCR5 receptor vaccine strategy in the control of mucosal SIV/HIV infection. Aids 2004, 18:25-36.
• [32]Bogers WM, Bergmeier LA, Oostermeijer H, ten Haaft P, Wang Y, Kelly CG, Singh M, Heeney JL, Lehner T: CCR5 targeted SIV vaccination strategy preventing or inhibiting SIV infection. Vaccine 2004, 22:2974-2984.
• [33]Klavinskis LS, Bergmeier LA, Gao L, Mitchell E, Ward RG, Layton G, Brookes R, Meyers NJ, Lehner T: Mucosal or targeted lymph node immunization of macaques with a particulate SIVp27 protein elicits virus-specific CTL in the genito-rectal mucosa and draining lymph nodes. J Immunol 1996, 157:2521-2527.
• [34]Lehner T, Bergmeier LA, Tao L, Panagiotidi C, Klavinskis LS, Hussain L, Ward RG, Meyers N, Adams SE, Gearing AJ, et al.: Targeted lymph node immunization with simian immunodeficiency virus p27 antigen to elicit genital, rectal, and urinary immune responses in nonhuman primates. J Immunol 1994, 153:1858-1868.
• [35]Guidry AJ, O’Brian CN, Oliver SP, Dowlen HH, Douglass LW: Effect of Whole Staphylococcus aureus and Mode of Immunization on Bovine Opsonizing Antibodies to Capsule. J Dairy Sci 1994, 77:2965-2974.
• [36]Ochsenbein AF, Sierro S, Odermatt B, Pericin M, Karrer U, Hermans J, Hemmi S, Hengartner H, Zinkernagel RM: Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 2001, 411:1058-1064.
• [37]Juillard GJ, Boyer PJ, Niewisch H, Hom M: Distribution and consequences of cell suspensions following intralymphatic infusion. Bull Cancer 1979, 66:217-228.
• [38]Juillard GJ, Boyer PJ, Snow HD: Intralymphatic infusion of autochthonous tumor cells in canine lymphoma. Int J Radiat Oncol Biol Phys 1976, 1:497-503.
• [39]Juillard GJ, Boyer PJ, Yamashiro CH: A phase I study of active specific intralymphatic immunotherapy (ASILI). Cancer 1978, 41:2215-2225.
• [40]Juillard GJ, Boyer PJ, Yamashiro CH, Snow HD, Weisenburger TH, McCarthy T, Miller RJ: Regional intralymphatic infusion (ILI) of irradiated tumor cells with evidence of distant effects. Cancer 1977, 39:126-130.
• [41]Finerty S, Stokes CR, Gruffydd-Jones TJ, Hillman TJ, Barr FJ, Harbour DA: Targeted lymph node immunization can protect cats from a mucosal challenge with feline immunodeficiency virus. Vaccine 2001, 20:49-58.
• [42]von Beust BR, Johansen P, Smith KA, Bot A, Storni T, Kundig TM: Improving the therapeutic index of CpG oligodeoxynucleotides by intralymphatic administration. Eur J Immunol 2005, 35:1869-1876.
• [43]Storni T, Ruedl C, Schwarz K, Schwendener RA, Renner WA, Bachmann MF: Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol 2004, 172:1777-1785.
• [44]Bourquin C, Anz D, Zwiorek K, Lanz AL, Fuchs S, Weigel S, Wurzenberger C, von der Borch P, Golic M, Moder S, et al.: Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity. J Immunol 2008, 181:2990-2998.
• [45]Martinez-Gomez JM, Johansen P, Erdmann I, Senti G, Crameri R, Kundig TM: Intralymphatic Injections as a New Administration Route for Allergen-Specific Immunotherapy. Int Arch Allergy Immunol 2009, 150:59-65.
• [46]Arbes SJ Jr, Gergen PJ, Elliott L, Zeldin DC: Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey. J Allergy Clin Immunol 2005, 116:377-383.
• [47]Verlato G, Corsico A, Villani S, Cerveri I, Migliore E, Accordini S, Carolei A, Piccioni P, Bugiani M, Lo Cascio V, et al.: Is the prevalence of adult asthma and allergic rhinitis still increasing? Results of an Italian study. J Allergy Clin Immunol 2003, 111:1232-1238.
• [48]Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. Beasley R and the International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet. 1998;351:1225–1232.
• [49]Wuthrich B, Schindler C, Medici TC, Zellweger JP, Leuenberger P: IgE levels, atopy markers and hay fever in relation to age, sex and smoking status in a normal adult Swiss population. SAPALDIA (Swiss Study on Air Pollution and Lung Diseases in Adults) Team. Int Arch Allergy Immunol 1996, 111:396-402.
• [50]Bousquet J, Lockey R, Malling HJ: Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998, 102:558-562.
• [51]Lockey RF: “ARIA”: global guidelines and new forms of allergen immunotherapy. J Allergy Clin Immunol 2001, 108:497-499.
• [52]Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR: Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991, 302:265-269.
• [53]Durham SR, Walker SM, Varga EM, Jacobson MR, O’Brien F, Noble W, Till SJ, Hamid QA, Nouri-Aria KT: Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999, 341:468-475.
• [54]Golden DB, Kwiterovich KA, Kagey-Sobotka A, Valentine MD, Lichtenstein LM: Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol 1996, 97:579-587.
• [55]Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S: Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001, 31:1392-1397.
• [56]Moller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen L, Koivikko A, Koller DY, Niggemann B, Norberg LA, et al.: Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002, 109:251-256.
• [57]Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC: Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol 1987, 79:660-677.
• [58]Lockey RF, Turkeltaub PC, Olive ES, Hubbard JM, Baird-Warren IA, Bukantz SC: The Hymenoptera venom study. III: Safety of venom immunotherapy. J Allergy Clin Immunol 1990, 86:775-780.
• [59]Stewart GE 2nd, Lockey RF: Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol 1992, 90:567-578.
• [60]Till SJ, Francis JN, Nouri-Aria K, Durham SR: Mechanisms of immunotherapy. J Allergy Clin Immunol 2004, 113:1025-1034. quiz 1035
• [61]Norman PS: Immunotherapy: 1999–2004. J Allergy Clin Immunol 2004, 113:1013-1023. quiz 1024
• [62]Vissers JL, van Esch BC, Hofman GA, Kapsenberg ML, Weller FR, van Oosterhout AJ: Allergen immunotherapy induces a suppressive memory response mediated by IL-10 in a mouse asthma model. J Allergy Clin Immunol 2004, 113:1204-1210.
• [63]Pierson-Mullany LK, Jackola D, Blumenthal M, Rosenberg A: Altered allergen binding capacities of Amb a 1-specific IgE and IgG4 from ragweed-sensitive patients receiving immunotherapy. Ann Allergy Asthma Immunol 2000, 84:241-243.
• [64]Senti G, Prinz Vavricka BM, Erdmann I, Diaz MI, Markus R, McCormack SJ, Simard JJ, Wuthrich B, Crameri R, Graf N, et al.: Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A 2008, 105:17908-17912.
• [65]Hylander T, Latif L, Petersson-Westin U, Cardell LO: Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis. J Allergy Clin Immunol 2013, 131:412-420.
• [66]Witten M, Malling HJ, Blom L, Poulsen BC, Poulsen LK: Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? J Allergy Clin Immunol 2013, 132:1248-1252. e1245
• [67]Kundig TM, Johansen P, Bachmann MF, Cardell LO, Senti G: Intralymphatic immunotherapy: Time interval between injections is essential. J Allergy Clin Immunol 2014, 133:930-931.
• [68]Siegrist CA. Vaccine Immunology. In Vaccines, 6th Edition. Edited by Plotkin SA: Elsevier; Saunders, Philadelphia 2013: 14–32
• [69]Malling HJ, Witten M, Poulsen LK: Intralymphatic immunotherapy: Time interval between injections is essential Reply. J Allergy Clin Immun 2014, 133:931-932.
• [70]Martinez-Gomez JM, Johansen P, Rose H, Steiner M, Senti G, Rhyner C, Crameri R, Kundig TM: Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy. Allergy 2009, 64:172-178.
• [71]Rhyner C, Kundig T, Akdis CA, Crameri R: Targeting the MHC II presentation pathway in allergy vaccine development. Biochem Soc Trans 2007, 35:833-834.
• [72]Crameri R, Fluckiger S, Daigle I, Kundig T, Rhyner C: Design, engineering and in vitro evaluation of MHC class-II targeting allergy vaccines. Allergy 2007, 62:197-206.
• [73]Senti G, Crameri R, Kuster D, Johansen P, Martinez-Gomez JM, Graf N, et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol. 2012;129:1290–6.